Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2023-05-19 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLB
Regulatory Filings Classification · 1% confidence The document is a formal company announcement from Genmab regarding the FDA approval of a new drug, EPKINLY. It details the clinical trial results, the nature of the drug, and safety information. While it contains significant information, it is structured as a 'Company Announcement' (labeled as 'Company Announcement no. 27') intended to inform the market of a specific regulatory event. It does not fit into the categories of financial reports (10-K, IR), transcripts (CT), or governance reports. As it is a general regulatory announcement regarding product development and approval, it falls under the RNS category.
2023-05-19 English
6-K
Foreign Filer Report
2023-05-10 English
6-K
Foreign Filer Report
2023-04-24 English
Legal Proceedings Report 2023
Legal Proceedings Report Classification · 1% confidence The document is a 'Company Announcement' dated April 24, 2023, detailing Genmab's decision to file an appeal regarding an arbitration award with Janssen. This announcement concerns a legal/dispute matter. While it relates to legal proceedings, the core content is an update on a specific legal action (arbitration appeal). This fits best under 'Legal Proceedings Report' (LTR). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it addresses a specific, material legal event. The document length is moderate (6070 chars), and it is the primary content, not just an announcement of another report, although it does have an attachment link.
2023-04-24 English
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Legal Proceedings Report Classification · 1% confidence The document is a company announcement regarding a legal appeal in an arbitration case between Genmab and Janssen. It details a specific legal proceeding and the company's intent to challenge an arbitration award. This falls under the category of legal proceedings or regulatory announcements. Since it is a specific update on a legal matter rather than a general regulatory filing, it is best classified as a Legal Proceedings Report (LTR).
2023-04-24 English
6-K
Foreign Filer Report
2023-04-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.